Slide 1: Filing cover letter: Presentation and Video Recording of Q4 FY23 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com May 24, 2023 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate
Slide 2: Q4 and full year FY23 Earnings Call
Q4 and full year FY23 Earnings Call May 24, 2023 B I O C O N L I M I T E D 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Opening Remarks
Opening Remarks B I O C O N L I M I T E D 33
Slide 5: Opening Remarks: Q4 FY23 Earnings Call
Opening Remarks: Q4 FY23 Earnings Call H I G H L E V E L S U M M ARY: F Y 2 3 T O TAL I N C O M E In INR Cr FY23 FY22 YoY % Strong revenue growth over last year, Total Revenues up 38% Generics 2,637 2,341 13 Completion of the landmark acquisiton of Viatris’ biosimilar Biosimilars 5,584 3,464 61 busi
Slide 6: Viatris biosimilar acquisition
Viatris biosimilar acquisition B U S I N E S S I N T E G R AT I O N N E T D E B T R E D U C T I O N Business integration progressing well Net Debt* at ~USD 1.9 billion as of Dec 2022 Viatris continues to provide commercial and other transition services to Biocon Biologics as part of a pre-agreed Tra
Slide 7: Financial Highlights Q4 and full year FY23
Financial Highlights Q4 and full year FY23 B I O C O N L I M I T E D 66
Slide 8: Financial Highlights: Q4 FY23
Financial Highlights: Q4 FY23 Consolidated (in ₹ Cr.) Q4 FY23 Q4 FY22 YoY % Biosimilars +114% | Research +31% | Generics - Total Revenue 3,929 2,476 59 Includes ₹109 Cr from Bicara stake dilution gain Core EBITDA1 1,260 809 56 Growth driven by Biosimilars & Research services % Margin 35% 33% Net R&D
Slide 9: Financial Highlights: FY23 (1/2)
Financial Highlights: FY23 (1/2) Consolidated (in ₹ Cr.) FY23 FY22 YoY % Biosimilars +61% | Research +23% | Generics +13% Total Revenue 11,550 8,397 38 Includes ₹217 Cr from Bicara stake dilution gain Core EBITDA1 3,807 2,669 43 Growth driven by Biosimilars & Research services % Margin 34% 32% Net R
Slide 10: Financial Highlights: FY23 (2/2)
Financial Highlights: FY23 (2/2) Consolidated (in ₹ Cr.) FY23 FY22 YoY % Net Profit 787 722 9 (before exceptional charge) Exceptional items during FY23: Exceptional Items • Deal related expenses of the Viatris transaction (net of tax and minority interest) (324) 74 • MAT credit balance charge on ado
Slide 11: Generics Q4 and full year FY23
Generics Q4 and full year FY23 B I O C O N L I M I T E D 10 10
Slide 12: Generics: Q4 & full year FY23 Update
Generics: Q4 & full year FY23 Update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Revenue growth for the quarter muted mainly due to product mix, margins lower due to price erosion in base business products Segment Revenue 717 717 0 Delivered revenue in-line with guidance of for the ful
Slide 13: Biosimilars Q4 and full year FY23
Biosimilars Q4 and full year FY23 B I O C O N L I M I T E D 12 12
Slide 14: Biosimilars: Q4 and full year FY23 Update
Biosimilars: Q4 and full year FY23 Update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Revenue 2,102 982 114 Q4 FY23 is the first full quarter with consolidated financials having both base and acquired business; guidance met Core EBITDA 742 382 95 % of revenue 39% 39% R&D investments in
Slide 15: Novels Q4 FY23
Novels Q4 FY23 B I O C O N L I M I T E D 14 14
Slide 16: Novels: Q4 FY23 update
Novels : Q4 FY23 update K E Y H I G H L I G H T S Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study) Pivotal Phase 1b clinical study of itolizumab for Lupus Nephritis (EQUALISE study) remains on track, top line data expected in 1
Slide 17: Research Services Q4 and full year FY23
Research Services Q4 and full year FY23 B I O C O N L I M I T E D 16 16
Slide 18: Research Services: Q4 & full year FY23 update
Research Services: Q4 & full year FY23 update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Biggest quarter ever. Strong growth with positive performances Segment Revenue 994 758 31 across all four divisions PBT 231 179 29% The growth of Discovery Services and Dedicated Centers remained
Slide 19: Concluding Remarks
Concluding Remarks B I O C O N L I M I T E D 18 18
Slide 20: Concluding remarks
Concluding remarks Final Dividend of ₹1.50 per share, representing 30% of face value of each share for FY23 recommended by the Board of Directors All business segments well positioned to grow in FY24 B I O C O N L I M I T E D 19
Slide 21: Q&A
Q&A B I O C O N L I M I T E D 20 20